With reference to previous studies using TTK- and PLK1-specific approaches (discussed above), and based on the MoA of BAL0891, loss of tumor suppressors, aberrant signal transduction/cell cycle modulation or even alterations in genes involved in mitotic progression itself may also have implications for tumor response to dual TTK/PLK1 inhibition. The gene discussed is TTK; the disease is neoplasm.